NASDAQ: ROIV ยท Biotechnology
Roivant Sciences (ROIV) fair value and price range
As of 19 Sep 2026, Faircurve's model values Roivant Sciences (ROIV) at $37.30 a share. The stock last closed at $38.99, which puts the model's fair value 4.3% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 21 Sep 2026. Roivant Sciences Ltd.
What price range does the model give ROIV?
The calibrated range for ROIV over 63 trading days is $34.88 to $48.12. It sits around the last close, and its width comes from the volatility that ROIV's own options imply (46% a year), calibrated weekly against realised prices (n = 2,982 past valuations, refreshed 19 Sep 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $23.97 to $56.15. In 45% of the simulations the fair value came out above the price the model ran on.
How does ROIV score on business quality?
Roivant Sciences's overall quality score is 19 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 0 | -36.1%ROIC | |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 19 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 50 | -71.6%Revenue growth, trailing | 33.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 36 | 1.1%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 12 | 4.06xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 3006.5 ptsEBITDA margin downside volatility, 5y |
How does ROIV compare with similar companies?
The companies in biotechnology closest to Roivant Sciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| INSM Insmed Incorporated | $121.00 | $121.16 | +0.1% | Low model confidence |
| ALNY Alnylam Pharmaceuticals, Inc. | $244.32 | $245.78 | +0.6% | Fairly valued |
| INCY Incyte Corporation | $124.65 | $140.51 | +12.7% | Fairly valued |
| UTHR United Therapeutics Corporation | $493.10 | $507.61 | +2.9% | Fairly valued |
| JAZZ Jazz Pharmaceuticals plc | $241.46 | $284.78 | +17.9% | Undervalued |
| NBIX Neurocrine Biosciences, Inc. | $143.96 | $145.31 | +0.9% | Fairly valued |
| EXEL Exelixis, Inc. | $57.22 | $60.58 | +5.9% | Fairly valued |
| MRNA Moderna, Inc. | $172.94 | $130.37 | -24.6% | Overvalued |
When does ROIV report earnings, and how has the stock reacted?
Roivant Sciences's next earnings report is scheduled for 9 Nov 2026. Companies can move their dates.
Options prices on 21 Sep 2026 imply a move of about 9.3% in either direction through the nearest expiry, about 24 days out. That is the size the market is pricing, not a direction. ROIV's 30 day implied volatility works out to about 13.2% over one month.
How ROIV moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 4.4%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | +5.0% |
| 20 May 2026 | +9.5% |
| 6 Feb 2026 | +30.9% |
| 10 Nov 2025 | +1.4% |
| 11 Aug 2025 | +0.7% |
| 29 May 2025 | +15.8% |
| 10 Feb 2025 | -3.7% |
| 12 Nov 2024 | +1.2% |
Roivant Sciences at a glance
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs.
- Market value
- $28.7B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $222M
- Consensus revenue growth, next fiscal year
- +539.8%
- Analysts with estimates
- 4
- Beta to the US market
- 0.90
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Roivant Sciences on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 12 Sep 2026 the model's fair value for ROIV was $38.28. As of 19 Sep 2026 it is $37.30, a change of -2.6%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Roivant Sciences's valuation
Is Roivant Sciences stock undervalued or overvalued?
Faircurve's model puts ROIV's fair value at $37.30 a share against a last close of $38.99, as of 19 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is ROIV's fair value?
$37.30 a share as of 19 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $23.97 to $56.15.
What price range does the model give ROIV?
$34.88 to $48.12 over 63 trading days. Ranges built this way held the price 60% of the time across 2,982 past valuations, refreshed 19 Sep 2026.
When does Roivant Sciences report earnings next?
The next report is scheduled for 9 Nov 2026. Companies can move their dates.
How much has ROIV moved on past earnings reports?
Across its last 8 reports the median two session move was 4.4%, ignoring direction. The largest was +30.9% around the report of 6 Feb 2026.
How confident is the model in this valuation?
Model confidence for ROIV is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.